Antibe Therapeutics' IPO

Antibe Therapeutics raised a round of funding on August 22, 2013. Investors include Public.

Antibe Therapeutics ("Antibe") is a public biotech company with a drug platform of therapeutics in pain and inflammation. Its lead drug, ATB-346, recently showed unequivocal superiority to naproxen in…

Articles about Antibe Therapeutics' IPO: